New study links Pfizer’s new RSV vaccine for pregnant women to preterm births

05/05/2024 / By Laura Harris

A recently published preprint study adds to the long list of evidence linking Abrysvo, Pfizer’s respiratory syncytial virus (RSV) vaccine for pregnant women, to higher incidences of preterm births.

The study, conducted by Canadian researchers at the University of Ottawa School of Epidemiology and Public Health, examined adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), the federal government’s vaccine adverse event database, following RSV immunization from Sept. 1, 2023, to Feb. 23, 2024. The researchers narrowed the scope of the extracted reports to pregnant women to analyze maternal age, gestational age at the time of vaccination, interval until the onset of the event and reported outcomes.

According to the study, the first post-authorization safety analysis of Pfizer’s RSV vaccine found the average time between vaccination and preterm birth was three days, with two-thirds of reported cases occurring within a week.

The study also found that out of the 77 reports filed in the database, with 55 percent categorized as serious incidents, preterm birth emerged as the foremost pregnancy-related adverse event. Preterm premature rupture of membranes, cesarean section, cervical dilatation and pregnancy-related hemorrhage follow preterm birth. Additionally, non-pregnancy-specific adverse events such as headaches, injection site erythema and injection site pain were also reported.

David Healy, a renowned drug safety expert and author of “Pharmageddon,” warned the public that the RSV vaccines have a 60-year history of causing problems.

“It looks like our latest efforts to overcome these problems have not helped and are leading to preterm births which have lifelong knock-on effects along with more serious RSV infections in children where these should be harmless,” said Healy. “Sixty years ago we recognized the problems and stopped. But now we seem determined to press ahead regardless. The intense push to get these vaccines means we will all have affected family members – this is not an abstract concern.”

Public and private health agencies still recommend Pfizer’s Abrysvo to pregnant women despite preterm risks

But despite all this, several private and public health agencies still recommend Pfizer’s Abrysvo for pregnant women.

In August 2023, the Food and Drug Administration (FDA) approved Pfizer’s Abrysvo for pregnant women to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through six months of age. (Related: Guinea pigs: Pfizer gets FDA approval to experiment on pregnant women with new RSV vaccine linked to premature birth.)

“RSV is a common cause of illness in children, and infants are among those at highest risk for severe disease, which can lead to hospitalization,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research at that time. “This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease.”

Following this, in September 2023, the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices recommended administering the vaccine to pregnant women between weeks 32 and 36 of their pregnancies to shield newborns from RSV-related lower respiratory tract illness after delivery. Even the American College of Obstetricians and Gynecologists advocates for a single dose of Pfizer’s RSV vaccine for expectant mothers in December 2023.

VaccineDamage.news has more information on dangerous and experimental new vaccinations.

Watch this clip from “Faithful Freedom with Teryn Gregson” on Red Voice Media discussing how the RSV vaccines are the new Wuhan coronavirus (COVID-19) vaccines.

This video is from the Red Voice Media channel on Brighteon.com.